430 related articles for article (PubMed ID: 22447567)
1. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
Ying S; Hamdy FC; Helleday T
Cancer Res; 2012 Jun; 72(11):2814-21. PubMed ID: 22447567
[TBL] [Abstract][Full Text] [Related]
2. DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair.
Ying S; Chen Z; Medhurst AL; Neal JA; Bao Z; Mortusewicz O; McGouran J; Song X; Shen H; Hamdy FC; Kessler BM; Meek K; Helleday T
Cancer Res; 2016 Mar; 76(5):1078-88. PubMed ID: 26603896
[TBL] [Abstract][Full Text] [Related]
3. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
[TBL] [Abstract][Full Text] [Related]
5. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
6. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
Kim JJ; Lee SY; Choi JH; Woo HG; Xhemalce B; Miller KM
Mol Cell; 2020 Oct; 80(2):327-344.e8. PubMed ID: 32966758
[TBL] [Abstract][Full Text] [Related]
7. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination.
Bryant HE; Petermann E; Schultz N; Jemth AS; Loseva O; Issaeva N; Johansson F; Fernandez S; McGlynn P; Helleday T
EMBO J; 2009 Sep; 28(17):2601-15. PubMed ID: 19629035
[TBL] [Abstract][Full Text] [Related]
8. WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells.
Datta A; Biswas K; Sommers JA; Thompson H; Awate S; Nicolae CM; Thakar T; Moldovan GL; Shoemaker RH; Sharan SK; Brosh RM
Nat Commun; 2021 Nov; 12(1):6561. PubMed ID: 34772932
[TBL] [Abstract][Full Text] [Related]
9. Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells.
Batenburg NL; Mersaoui SY; Walker JR; Coulombe Y; Hammond-Martel I; Wurtele H; Masson JY; Zhu XD
Nucleic Acids Res; 2021 Dec; 49(22):12836-12854. PubMed ID: 34871413
[TBL] [Abstract][Full Text] [Related]
10. Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent Degradation of Nascent DNA in the Absence of Brca2 and Stable Rad51 Nucleofilaments.
Kolinjivadi AM; Sannino V; De Antoni A; Zadorozhny K; Kilkenny M; Técher H; Baldi G; Shen R; Ciccia A; Pellegrini L; Krejci L; Costanzo V
Mol Cell; 2017 Sep; 67(5):867-881.e7. PubMed ID: 28757209
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
12. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribosyl)ation of TIMELESS limits DNA replication stress and promotes stalled fork protection.
Rageul J; Lo N; Phi AL; Patel JA; Park JJ; Kim H
Cell Rep; 2024 Mar; 43(3):113845. PubMed ID: 38393943
[TBL] [Abstract][Full Text] [Related]
14. MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
Lemaçon D; Jackson J; Quinet A; Brickner JR; Li S; Yazinski S; You Z; Ira G; Zou L; Mosammaparast N; Vindigni A
Nat Commun; 2017 Oct; 8(1):860. PubMed ID: 29038425
[TBL] [Abstract][Full Text] [Related]
15. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.
Ewald B; Sampath D; Plunkett W
Cancer Res; 2008 Oct; 68(19):7947-55. PubMed ID: 18829552
[TBL] [Abstract][Full Text] [Related]
16. Stalled replication forks within heterochromatin require ATRX for protection.
Huh MS; Ivanochko D; Hashem LE; Curtin M; Delorme M; Goodall E; Yan K; Picketts DJ
Cell Death Dis; 2016 May; 7(5):e2220. PubMed ID: 27171262
[TBL] [Abstract][Full Text] [Related]
17. Human CST complex protects stalled replication forks by directly blocking MRE11 degradation of nascent-strand DNA.
Lyu X; Lei KH; Biak Sang P; Shiva O; Chastain M; Chi P; Chai W
EMBO J; 2021 Jan; 40(2):e103654. PubMed ID: 33210317
[TBL] [Abstract][Full Text] [Related]
18. POLθ prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2/RAD51 by filling lagging-strand gaps.
Mann A; Ramirez-Otero MA; De Antoni A; Hanthi YW; Sannino V; Baldi G; Falbo L; Schrempf A; Bernardo S; Loizou J; Costanzo V
Mol Cell; 2022 Nov; 82(22):4218-4231.e8. PubMed ID: 36400008
[TBL] [Abstract][Full Text] [Related]
19. Replication fork reversal triggers fork degradation in BRCA2-defective cells.
Mijic S; Zellweger R; Chappidi N; Berti M; Jacobs K; Mutreja K; Ursich S; Ray Chaudhuri A; Nussenzweig A; Janscak P; Lopes M
Nat Commun; 2017 Oct; 8(1):859. PubMed ID: 29038466
[TBL] [Abstract][Full Text] [Related]
20. CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress.
Przetocka S; Porro A; Bolck HA; Walker C; Lezaja A; Trenner A; von Aesch C; Himmels SF; D'Andrea AD; Ceccaldi R; Altmeyer M; Sartori AA
Mol Cell; 2018 Nov; 72(3):568-582.e6. PubMed ID: 30344097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
